
==== Front
World J Diabetes
WJD
World Journal of Diabetes
1948-9358
Baishideng Publishing Group Inc

jWJD.v15.i9.pg1862
10.4239/wjd.v15.i9.1862
96508
Review
Selection of dialysis methods for end-stage kidney disease patients with diabetes
Hu YH et al. Dialysis choice for ESKD diabetics
Hu Yao-Hua Department of Nephrology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China

Liu Ya-Li Department of Nephrology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China

Meng Ling-Fei Department of Nephrology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China

Zhang Yi-Xian Department of Nephrology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China

Cui Wen-Peng Department of Nephrology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China. wenpengcui@163.com

Author contributions: Hu YH wrote the main manuscript text; Liu YL and Zhang YX prepared tables 1-2; Meng LF participated in revising the manuscript; Cui WP designed this study and reviewed this manuscript.

Supported by Science and Technology Department of Jilin Province, No. YDZJ202201ZYTS110 and No. 20200201352JC .

Corresponding author: Wen-Peng Cui, MD, PhD, Doctor, Professor, Department of Nephrology, The Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, Jilin Province, China. wenpengcui@163.com

15 9 2024
15 9 2024
15 9 18621873
8 5 2024
3 7 2024
29 7 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
The increasing prevalence of diabetes has led to a growing population of end-stage kidney disease (ESKD) patients with diabetes. Currently, kidney transplantation is the best treatment option for ESKD patients; however, it is limited by the lack of donors. Therefore, dialysis has become the standard treatment for ESKD patients. However, the optimal dialysis method for diabetic ESKD patients remains controversial. ESKD patients with diabetes often present with complex conditions and numerous complications. Furthermore, these patients face a high risk of infection and technical failure, are more susceptible to malnutrition, have difficulty establishing vascular access, and experience more frequent blood sugar fluctuations than the general population. Therefore, this article reviews nine critical aspects: Survival rate, glucose metabolism disorder, infectious complications, cardiovascular events, residual renal function, quality of life, economic benefits, malnutrition, and volume load. This study aims to assist clinicians in selecting individualized treatment methods by comparing the advantages and disadvantages of hemodialysis and peritoneal dialysis, thereby improving patients’ quality of life and survival rates.

Diabetes
End-stage kidney disease
Hemodialysis
Peritoneal dialysis
Dialysis methods selection
==== Body
pmc Core Tip: The prevalence of diabetes is leading to an increase in the number of End-stage kidney disease (ESKD) patients with diabetes. Dialysis is the most commonly accepted treatment for ESKD patients. However, the optimal dialysis method for diabetic ESKD patients remains controversial. Diabetic ESKD patients often present with complex conditions and numerous complications. This article reviews recent literature on renal replacement therapy to determine the most suitable dialysis method for diabetic ESKD patients. This review is the first to evaluate the benefits of different dialysis types for diabetic ESKD patients across nine aspects.

INTRODUCTION

End-stage kidney disease (ESKD) is a global health concern with a significantly high mortality rate[1,2]. The prevalence of ESKD in the United States increased by 41.8% from 2000 to 2019. Among Asians, the prevalence increased by 149.5%, the largest rise among all racial and ethnic groups[3]. The number of ESKD patients with diabetes is increasing with the rise in the prevalence of diabetes[4]. Currently, the commonly used treatment for ESKD includes hemodialysis (HD) and peritoneal dialysis (PD)[5,6]. ESKD patients with diabetes undergoing dialysis have higher cardiovascular risks and mortality rates than non-diabetic ESKD patients[7]. Furthermore, ESKD patients with diabetes are at increased risk of complications, including blood sugar fluctuations and infections. Therefore, dialysis treatment for ESKD patients with diabetes is more complicated. Selecting appropriate treatment strategies for these patients is crucial. This study spe-cifically highlights the evidence types considered, including randomized controlled trials, cohort studies, large-sample retrospective studies (sample size ≥ 500), and case-control studies. This review aims to systematically organize and compile available evidence for a comprehensive analysis. Including high-quality studies ensures reliable and trustworthy results. Selecting the dialysis method with the greatest clinical advantages for patients has been challenging. However, there are only a few articles that suggest the type of dialysis method suitable for ESKD patients with diabetes, and the evidence presented is inconsistent[8,9]. This article reviews recent literature on renal replacement therapy to determine the most suitable dialysis method for diabetic ESKD patients, focusing on nine key aspects: Survival rate, glucose metabolism disorders, infectious complications, cardiovascular events, residual renal function (RRF), quality of life, economic benefits, malnutrition, and volume load.

LITERATURE SEARCH AND EVIDENCE SELECTION METHODS

A comprehensive literature search was conducted using the PubMed database. Initially, titles and abstracts were reviewed to identify relevant studies, followed by a thorough full-text evaluation to ensure scientific rigor and relevance. Studies were selected based on nine key criteria: Survival rate, glucose metabolism disorders, infectious complications, cardiovascular events, RRF, quality of life, economic benefits, malnutrition, and volume load. This study discusses these criteria in detail and provides clinical evidence to support the analysis, offering guidance for clinical practice. Studies evaluating diabetic patients undergoing HD or PD for ESKD and providing data on key assessment criteria were included. Articles were excluded if full texts were unavailable or data were incomplete.

COMPARISON OF DIFFERENT TREATMENT METHODS FOR DIABETIC ESKD PATIENTS

Survival rate

The survival rate of dialysis patients is an important indicator for evaluating patient benefit. However, the impact of dialysis methods on the survival of diabetic ESKD patients remains debated.

The survival rates of diabetic ESKD patients undergoing HD and PD are similar: Several studies have indicated that PD and HD offer comparable survival rates for diabetic ESKD patients[10-14]. A propensity-matched score study in Guangdong Province, China, compared the mortality rates of PD and HD in 268 ESKD patients with type 2 diabetes (T2D). The study revealed that PD and HD had similar mortality rates, both in the first 2 years and beyond 2 years of starting dialysis treatment[10]. Additionally, a propensity-matching score study on 210 diabetic ESKD patients from 2012 to 2019 indicated similar survival rates for T2D-ESKD patients undergoing PD and HD[11]. Similar results were observed in a Norwegian study[13]. However, all the aforementioned studies were retrospective. A 2020 systematic review of 214 papers, including 17 cohort studies and 113578 patients, found no significant difference in mortality risk between PD and HD (HR: 1.06, 95%CI: 0.99-1.14). Subgroup meta-analysis showed that patients with diabetes had HR: 1.09 (95%CI: 0.98-1.21), while those without diabetes had HR: 0.99 (95%CI: 0.90-1.09)[14]. No randomized controlled trial (RCT) to support this analysis requires further RCT verification.

Diabetic ESKD patients have a higher survival rate after PD than HD: Some studies have indicated that ESKD patients with diabetes have a higher survival rate with PD than with HD[15-17]. A 2010 retrospective study by Weinhandl et al[16] in the United States found that PD had a survival advantage over HD in the first year after starting dialysis, whereas HD had a survival advantage after one year. Furthermore, a 2016 Korean prospective cohort study on 902 diabetic patients indicated that according to the multivariate analysis, PD has a higher survival advantage than HD (HR: 0.59, 95%CI: 0.37-0.94, P = 0.03), and good blood sugar control is associated with better survival in PD patients[15]. Overall, these studies have indicated that the survival rate of diabetic patients undergoing dialysis is associated with dialysis method and time. With the continuous advancement of PD technology, the survival advantage of diabetic patients undergoing PD is gradually increasing. A 2018 single-center retrospective study in Shanghai, China, reported that the 3-year survival rate of PD patients was significantly higher than that of HD patients (log-rank = 5. 582, P = 0.018)[17]. Therefore, it can be inferred that PD offers increased survival rates for diabetic ESKD patients compared to HD.

Diabetic ESKD patients have a lower survival rate after PD than HD: Studies suggest that diabetic ESKD patients have a reduced survival rate with PD compared to HD[18-21]. A 2012 Canadian registry study found that the mortality rate of PD among elderly diabetic women was higher than that of HD[18]. Furthermore, a 2015 retrospective cohort study in Taiwan indicated similar results for ESKD patients with diabetes and a history of stroke. However, in ESKD patients without diabetes and a history of stroke, HD and PD had similar overall survival rates[19]. A 2017 retrospective study by I-Kuan Wang et al[20] suggested that the survival rate of elderly diabetic ESKD patients undergoing PD was lower than that for HD. A systematic review conducted by Cecile Couchoud et al[9] also revealed an elevated risk of mortality in elderly and frail patients undergoing PD treatment. A 2017 South Korean study confirmed this conclusion[21]. However, all these studies are based on clinical databases, and variables missing in the database cannot be adjusted, which may interfere with the results. Furthermore, the differences in the results of these studies may be caused by differences in the populations included. Table 1 indicates specific information on PD and HD survival studies.

Table 1 Summary of peritoneal dialysis and hemodialysis survival-related research information

Year of publication	Ref.	Literature source	Area	Research methods	Sample size	Follow-up time	Conclusion	
2007	Couchoud et al[9]	Nephrology Dialysis Transplantation	France	Register for research	3512	2002-2005	Within 2 years, patients undergoing PD and HD had similar death outcomes	
2010	Weinhand et al[16]	J Am Soc Nephrol	United States	Propensity matching study	12674	2003-2008	The overall intention-to-treat risk of mortality after dialysis initiation was 8% lower in the PD group than in matched HD patients	
2012	Yeates et al[18]	Nephrology Dialysis Transplantation	Canada	Register for research	46839	1991-2007	Among patients with diabetes, the mortality rate of PD patients is higher than that of HD patients	
2015	Waldum-Grevbo et al[13]	BMC Nephrology	Norway	Propensity matching study	1364	2005-2012	Five-year all-cause or cardiovascular mortality in PD as an initial dialysis modality is similar to HD	
2015	Wang et al[19]	International Urology and Nephrology	Taiwan, China	Retrospective cohort study	1950	2000-2010	Among ESKD patients with a history of stroke, mortality in patients with diabetic PD is higher than that in patients with diabetic HD	
2016	Lee et al[15]	Medicine	Korea	Prospective cohort study	902	2008. 8-2013. 12	Among diabetic dialysis patients, the overall survival rate of PD patients is significantly higher than that of HD patients	
2017	Kim et al[21]	The Korean Journal of Internal Medicine	Korea	Register for research	32280	2005. 1. 1-2008. 12. 31	PD mortality rate is higher than HD in diabetic ESKD patients	
2018	Wang et al[20]	European Journal of Internal Medicine	Taiwan, China	Retrospective cohort study	53103	2005. 1. 1-2011. 12. 31	Icodextrin mitigates the survival disadvantage of PD relative to HD in patients with diabetes	
2021	Liu et al[10]	International Urology and Nephrology	China	Propensity matching study	268	2012. 1-2017. 12	In patients with type 2 diabetes, mortality rates are similar between PD and HD	
2023	Xu et al[11]	Ther Apher Dial	China	Retrospective cohort study	281	2012. 1-2019. 12	Survival rates are similar in patients with diabetes and end-stage kidney disease treated with HD and PD	
ESKD: End-stage kidney disease; HD: Hemodialysis; PD: Peritoneal dialysis.

Despite the similar survival rates for PD and HD, PD is often recommended as the first dialysis method, particularly for patients with a long life expectancy, younger age, and better glycemic control. For elderly and frail patients, the choice of PD treatment should be cautious[9]. Treatment decisions must be tailored to the individual, considering both patient preferences and comorbidities.

Glucose metabolism disorder

Blood glucose fluctuations are an important characteristic of aberrant glucose metabolism. Poor blood sugar control promotes the progression of diabetic nephropathy[22]. On the other hand, tight glycemic control reduces the risk of cardiovascular disease (CVD) and improves outcomes in acute coronary syndromes[23].

Glucose metabolism in diabetic ESKD patients receiving PD: Patients who undergo PD treatment are exposed to glucose dialysate for a long time, and the total glucose absorbed is 100-300 g/d, accounting for 20% of the total body energy[24]. Therefore, diabetic PD patients absorb large amounts of glucose and are prone to glucose metabolism disorders. Takatori et al[25] conducted a randomized controlled study and found that icodextrin helps control blood sugar and fluid levels in patients, thereby improving technical survival. In diabetic patients, icodextrin can reduce glucose intake; however, there are also risks of allergies and toxic accumulation of maltose. Therefore, new PD solutions suitable for diabetic patients require continuous research.

Glucose metabolism in diabetic ESKD patients receiving HD: A retrospective study in Nanjing, China, included 46 ESKD patients undergoing HD and found that these patients had greater blood sugar fluctuations than non-diabetic patients[26]. Furthermore, a study from China’s People’s Liberation Army General Hospital indicated that elderly diabetic ESKD patients receiving HD had higher blood sugar fluctuations on dialysis days than on non-dialysis days and experienced more frequent hypoglycemia[27]. Diabetic HD patients are primarily at risk for HD-related hypoglycemia. Using glucose-containing dialysate in these patients can reduce blood sugar fluctuations; however, HD-related hypoglycemia may still occur[28-30].

Comparison of blood glucose fluctuations between diabetic ESKD patients undergoing HD and PD: A retrospective study in Nanjing, China, compared glucose metabolism in 64 ESKD patients with T2D undergoing PD and HD. The study revealed that blood glucose fluctuations in diabetic patients undergoing HD were greater than in those undergoing PD. PD requires a larger dose of insulin than HD for the same blood glucose level[31], likely because PD patients consume excessive glucose from peritoneal dialysate and require more insulin. Furthermore, patients receiving HD develop insulin resistance and hyperglycemia because of insulin accumulation before dialysis and are prone to increased insulin sensitivity and prolonged exogenous insulin half-life after dialysis. Moreover, HD is associated with hypoglycemia, causing significant blood sugar fluctuation in patients. For patients with poor blood glucose control, PD is recommended as the initial dialysis method. Applying icodextrin PD solution can stabilize blood glucose, but attention must be paid to insulin dosage. Few articles address the impact of HD or PD on glucose metabolism in diabetic ESKD patients, and further confirmation requires RCTs or prospective studies.

Infectious complications

Diabetic patients have reduced immunity and are prone to infection[32]. Furthermore, infections are an important cause of increased mortality in diabetic dialysis patients.

Infection status of diabetic ESKD patients receiving PD: The main complications of PD infection include peritonitis, catheter outlet, and subcutaneous tunnel infection. Of these, peritonitis is the most common complication in patients undergoing PD. Furthermore, diabetes is an independent risk factor for death in peritonitis patients[33,34], which might be because diabetic patients are prone to multiple infections due to accelerated peritoneal fibrosis and persistent high blood sugar[32,35]. Some studies have found that diabetes does not increase the incidence of peritonitis (P < 0.01)[36]. However, the impact of diabetes on the incidence of catheter-related infections remains controversial, requiring further research[37,38]. Lee et al[39] conducted a retrospective study and indicated that diabetic ESKD patients who underwent stepped-up PD had shorter hospital stays and lower incidence of peritonitis than full-dose PD, which might be linked with fewer exchanges and less glucose exposure in the incremental PD group[40,41]. There are few studies on the application of incremental PD in diabetic patients, and more prospective studies are needed for confirmation.

Infection status of diabetic ESKD patients receiving HD: A study from Singapore on HD patients between January 1, 2010, and December 31, 2012, revealed that the incidence of catheter-related bloodstream infection and exit site infection was 0.75/1000 and 0.50/1000 catheter days, respectively[42]. Furthermore, the infection rate associated with HD performed with tunnel catheter is 17.6 times higher than that performed with arteriovenous fistula. The most common pathogenic bacteria is Staphylococcus aureus[43,44]. The 2022 USRDS data indicated that home HD patients have relatively stable hospitalization rates for sepsis[45]. Overall, the risk of death from catheter-related infections is increased in HD.

Comparison of infection complications between diabetic ESKD patients undergoing HD and PD: In addition to the risk of vascular access infection, patients undergoing HD are more susceptible to infection than those undergoing PD. A Danish study on 9997 ESKD patients revealed that HD has a higher incidence of bacteremia than PD. Diabetes is a risk factor for ESKD bacteremia[46]. However, some studies have found no significant difference in infection-related mortality between HD and PD (HR: 1.341, 95%CI: 0.453-3.969)[47]. Additionally, PD and HD patients had similar overall infection rates but different types of infection and risk over time. HD patients have a particularly high risk of bacteremia in the first 90 days, whereas the PD cohort shows no significant difference in peritonitis risk over time[48].

Patients with ESKD and comorbid diabetes may benefit from PD due to its advantages in preventing and managing infectious complications. Implementing an incremental PD approach could lower the incidence of infections and hospitalizations. Individualizing the selection of dialysis modality based on the patient’s clinical circumstances is crucial to optimize treatment safety and efficacy. Current studies in this field are limited and warrant high-quality clinical research.

Cardiovascular events

The ESKD complicated by renal anemia is characterized by increased cardiac output, elevated extracellular fluid increasing cardiac preload, and secondary hyperparathyroidism, which can also result in left ventricular dysfunction, metabolic acidosis, and electrolyte disorders (such as hyperemia and potassium imbalance), can cause abnormalities in cardiac conduction and contractility[49]. All these factors keep the heart in a high-load state, causing ventricular dilation, hypertrophy, decreased myocardial contractility, and heart failure[50]. It has already been reported that CVD is the leading cause of death in diabetic patients on dialysis[51].

Morbidity and mortality of cardiovascular events in patients with ESKD: The literature suggests that ESKD patients have a higher cardiovascular morbidity rate. Korean National Health Insurance Service data from 2004 to 2007 have indicated the incidence rate of cardiovascular events in patients undergoing PD (37.3/1000 person-years) and HD (33.1/1000 person-years)[52]. A 2022 study from Singapore included 5,309 patients (4449 HD and 860 PD) and found that nearly one-third of the patients died from cardiovascular events[53]. In ESKD patients, regardless of PD or HD, more than half of the deaths from known causes are related to CVD (including stroke, acute myocardial infarction, arteriosclerotic heart disease, congestive heart failure (CHF), cardiovascular accident, and cardiac arrest)[45]. Furthermore, CVD is also a leading cause of death in diabetic ESKD patients[51].

Comparison of cardiovascular events between diabetic ESKD patients undergoing HD and PD: Non-diabetic patients receiving PD generally have more stable hemodynamics and a lower incidence of cardiovascular events than those undergoing HD[54,55]. In contrast, diabetic patients undergoing PD have a higher mortality rate from cardiovascular events than those on HD[47]. A Taiwan research group conducted a retrospective study using the propensity matching score method on 6516 patients in the HD and PD groups. The study found no significant difference in the overall risk of new major ischemic cardiac events in patients undergoing HD and PD. Moreover, patients undergoing HD have an increased risk of new-onset CHF than PD during the first year of treatment[54]. This might be because extracorporeal blood filtration during HD alters the hemodynamics, which increases the risk of cardiovascular complications. Diabetic patients have vascular calcification and are more susceptible to bleeding risks[55]. A prospective cohort study on 1347 (258 PD and 1089 HD) patients revealed that CVD-related mortality in diabetic patients receiving PD was significantly higher than those receiving HD (HD vs PD: HR: 0.37)[47], consistent with the research of Hu et al[56]. Studies indicate that HD is more effective in mitigating cardiovascular complications and reducing mortality rates in individuals with ESKD and comorbid diabetes. For patients with high-risk factors for cardiovascular events, HD may be the optimal dialysis modality for those with ESKD and diabetes.

RRF

Generally, RRF is measured by 24-hour urea and creatinine clearance; however, serum cystatin C can also be used to predict RRF[57]. Maintaining RRF is important and difficult for ESKD patients. Whether using PD or HD, RRF is closely related to patient survival[58,59]. PD has been observed to have a better protective effect on RRF than HD. Furthermore, with the improvements in the PD model and peritoneal dialysate, the protective effect of PD on RRF has become more prominent[57,60]. A retrospective study by Lee et al[39] found that incremental PD better protects the RRF of diabetic ESKD patients, allowing more free time for activities. This may be due to a lower glucose load and ultrafiltration, which reduces RRF loss[61]. Moreover, Htay et al[62] also indicated that using biocompatible PD fluid and less glucose exposure can better preserve the patient’s RRF. The biocompatible PD fluid can reduce exposure to glucose degradation products, thereby reducing renal tubular epithelial cell apoptosis[63]. Diabetes is a risk factor for increased RRF loss. Compared to patients undergoing PD, those receiving HD experience more rapid RRF loss, possibly due to hemodynamic instability[64-67]. Current research indicates that PD has clear advantages in maintaining RRF in diabetic patients. This is mainly due to its hemodynamic stability and the use of biocompatible dialysate, which helps slow the loss of RRF. Therefore, PD is more suitable for these patients.

Quality of life

People with ESKD often experience anxiety, depression, and reduced quality of life[68,69]. The impact of dialysis treatment on lifestyle, disease burden, and quality of life is very important to patients and their families. The HD and PD methods have different effects on patient’s quality of life, kidney disease burden, and depression in different countries[69].

Quality of life of diabetic ESKD patients undergoing PD: The PD treatment makes it easier for patients to work and socialize more often because they can stay at home. The application of automated PD (APD) brings more convenience to patients’ lives. Sun et al[70] found that the patients undergoing APD had a higher quality of life than those receiving traditional PD, primarily because APD patients continued the treatment at night, allowing them to work and live normally during the day. The quality-of-life benefits of APD are widely recognized.

Quality of life of diabetic ESKD patients undergoing HD: Diabetic ESKD patients undergoing HD often suffer from protein-energy malnutrition and muscle atrophy, reducing their quality of life[71]. Furthermore, Dembowska et al[72] identified that HD patients have an elevated risk of developing oral mycosis, osteoporosis, rheumatoid arthritis, coronary heart disease, etc., which seriously affects their quality of life. Moreover, elderly HD patients are at higher risk of developing depression[73].

Comparison of quality of life between diabetic ESKD patients undergoing HD and PD: Studies have generally found that patients undergoing PD have a better quality of life than those undergoing HD. For instance, Mathew et al[74] showed that compared with HD, patients with PD had better work lives due to their flexible treatment time[75,76]. Moreover, there are fewer restrictions on diet and activities, which significantly reduces patient anxiety, allowing a better standard of life[77,78], consistent with multiple studies[79-81]. However, some research indicates that HD has advantages in physical function and sleep quality[82,83]. Additionally, the literature also reports that for elderly patients, the quality of life is similar for both PD and HD[84,85]. Current research generally indicates that patients undergoing PD have a better quality of life than those undergoing HD. However, investigations on the quality of life of diabetic patients are limited and require more evidence. PD is often preferred for diabetic ESKD patients due to its adaptability and convenience, allowing treatment at home while maintaining normal daily activities. The use of APD can further improve overall quality of life. For elderly patients, the effects of PD and HD are comparable. Therefore, PD is generally considered the more advisable treatment option.

Economic benefits

The ESKD imposes a huge burden on the country in terms of public health expenditure and medical costs[86]. PD is generally considered to have better economic benefits than HD. A retrospective study on 100 patients in the United States found that the hospitalization rate and total cost of treatment for patients undergoing PD were significantly lower than that of HD[87]. A study in Taiwan and China also confirmed that the total cost of PD treatment is lower than that of HD, and the opportunity cost savings are more obvious, especially for patients with fixed jobs[88]. Furthermore, Shukri et al[89] also reached a similar conclusion. Moreover, in a study in Hong Kong, China, the lifetime treatment cost of PD and HD was US$ 76915 (7.13 quality-adjusted life years) and US$ 142389 (6.58 QALYs), respectively. Therefore, PD is more cost-effective than HD, supporting the existing PD priority policy[90]. Overall, PD can reduce patients’ economic burden, meet basic needs, and achieve better socio-economic benefits for both developed and developing countries[91].

Malnutrition

Malnutrition is a major complication in ESKD patients due to low nutritional intake, increased catabolism, and elevated protein loss caused by dialysis. Malnutrition significantly affects dialysis patients’ quality of life and increases mortality[92]. Malnutrition is assessed using indicators such as serum albumin, subjective global assessment score, elderly nutritional risk index, and protein energy consumption[93,94]. Lowrie et al[95] reported that low albumin levels are closely related to death and that malnutrition is a significant factor in patient mortality, consistent with findings by Wu et al[96].

Nutritional status of diabetic ESKD patients undergoing PD: PD treatment can result in excessive protein loss through the peritoneum, reduced appetite from continuous glucose absorption, and a feeling of abdominal fullness due to excessive PD fluid, all contributing to malnutrition. A study by Prasad et al[97] found that most PD patients had protein and energy intakes lower than NKF-K/DOQI recommendations, with many already malnourished at the beginning of PD. Additionally, PD patients with comorbidities have lower nutritional intake[98]. Therefore, these patients face significant challenges related to malnutrition.

Nutritional status of diabetic ESKD patients undergoing HD: Malnutrition in diabetic HD patients is associated with infection, elevated blood sugar, increased muscle breakdown, gastroparesis, diarrhea, and inadequate dialysis. Silva et al[99] indicated that diabetic patients undergoing HD are at increased risk of malnutrition, which might be linked with insufficient nutritional intake, consistent with many studies[100,101]. Furthermore, HD treatment causes chronic inflammation, low nutrient intake, and increased catabolism, which decreases muscle and fat mass[102,103]. This may also be affected by factors such as anorexia[104], energy metabolism disorder, metabolic acidosis, etc. Therefore, regular nutritional monitoring of patients is essential.

Comparison of nutritional status between diabetic ESKD patients undergoing HD and PD: Many researchers currently believe that PD poses a higher risk of malnutrition than HD. Xu et al[105], in their retrospective study, revealed that the PD group had lower total protein and albumin levels than the HD group, possibly due to protein loss with the dialysate. A multicenter study of 487 patients found that those under 65 years old undergoing PD were more likely to be mal-nourished than those undergoing HD, while in those over 75 years old, HD increased the risk of malnourishment compared to PD[106]. Improving the nutritional status of ESKD patients is crucial for better patient prognosis. Studies suggest that PD poses a higher risk of malnutrition, particularly in younger patients. In contrast, HD may increase the risk of malnutrition in older patients. Individualized dialysis regimens should be tailored to the unique nutritional needs of each patient.

Fluid overload

Fluid overload is related to excessive fluid intake by the body and is a common complication in dialysis patients with ESKD. Furthermore, it is an independent risk factor for CVD and death in ESKD patients[107]. The patients’ body volume load is primarily assessed via multifrequency electrical impedance analysis (BIA). Moreover, it has been inferred that PD is more prone to fluid overload than HD. According to a Chinese single-center cross-sectional study on 307 continuous ambulatory peritoneal dialysis patients, the incidence of fluid overload was 66.8[108]. Zoccali et al[109] also suggested that over 50% of HD patients experience fluid overload. ESKD patients undergoing PD are more likely to experience fluid overload than those on HD, and it is not easy to detect, possibly due to increased dialysate intakes[110]. Eldehni et al[8] have also discovered that individuals with diabetes face an increased risk of fluid overload during PD treatment. This could be linked to the absorption of glucose, loss of protein, and malnutrition. Fluid overload is a common complication of PD and HD, requiring strict water and salt intake restrictions. HD may be a more favorable choice for diabetic ESKD patients to better control volume overload and reduce related complications. Strict management of fluid and salt intake is critical for patients undergoing both HD and PD.

CONCLUSION

In summary, diabetic ESKD patients face complex conditions and numerous complications. HD and PD each have advantages and disadvantages, making the selection of the first-choice dialysis method challenging. Dialysis methods should be selected based on the patient’s condition, family economic status, peritoneal status, vascular access conditions, and regional medical insurance policies to achieve better survival rates and quality of life. A just and ethical approach to decision-making prioritizes patient autonomy and shared decision-making, ensuring each patient’s individual needs are carefully considered. Furthermore, the survival rates of diabetic ESKD patients under different dialysis methods remain debated. Table 2 summarizes studies comparing diabetic ESKD patients undergoing PD and HD. There is currently a lack of prospective clinical research on glucose metabolism, infectious complications, RRF, malnutrition, and fluid overload. Therefore, further research on these factors is warranted. Future research should implement a weighted scoring system, allocating weights to critical aspects of dialysis options for diabetic patients based on clinical evidence and their impacts. Dialysis methods will then be evaluated and scored based on empirical data, with the highest-scoring method being prioritized for recommendation. This approach aims to facilitate personalized treatment plans, enhancing patients’ quality of life and survival rates.

Table 2 Comparative summary of studies on peritoneal dialysis and hemodialysis in end-stage kidney disease patients with diabetes

Project	Randomized controlled study	Array research	
Forward-looking	Retrospective	
Survival rate	×	√	√	
Glucose metabolism disorder	×	×	√	
Infectious complications	×	×	×	
Cardiovascular events	×	√	√	
Residual renal function	×	×	√	
Quality of life	×	√	√	
Economic benefits	×	×	√	
Malnutrition	×	×	√	
Fluid overload	×	×	×	

ACKNOWLEDGEMENTS

Thanks to the strong support of the research team that made this article possible.

Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Corresponding Author's Membership in Professional Societies: Chinese Society of Nephrology, No. D01.

Specialty type: Endocrinology and metabolism

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade A, Grade A, Grade B, Grade C, Grade C

Novelty: Grade B, Grade B, Grade B

Creativity or Innovation: Grade B, Grade B, Grade B

Scientific Significance: Grade B, Grade B, Grade B

P-Reviewer: Cai L; Feizi A; Labusca L; Shalaby MN S-Editor: Qu XL L-Editor: A P-Editor: Yuan YY
==== Refs
1 Kalantar-Zadeh K Jafar TH Nitsch D Neuen BL Perkovic V Chronic kidney disease Lancet 2021 398 786 802 34175022
2 Li HL Tai PH Hwang YT Lin SW Lan LC Causes of Hospitalization among End-Stage Kidney Disease Cohort before and after Hemodialysis Int J Environ Res Public Health 2022 19
3 Kuehn BM End-stage Kidney Disease Doubles JAMA 2022 327 1540
4 Kleinaki Z Kapnisi S Theodorelou-Charitou SA Nikas IP Paschou SA Type 2 diabetes mellitus management in patients with chronic kidney disease: an update Hormones (Athens) 2020 19 467 476 32500461
5 Miyata Y Obata Y Mochizuki Y Kitamura M Mitsunari K Matsuo T Ohba K Mukae H Nishino T Yoshimura A Sakai H Periodontal Disease in Patients Receiving Dialysis Int J Mol Sci 2019 20
6 Jin DC Yun SR Lee SW Han SW Kim W Park J Kim YK Lessons from 30 years' data of Korean end-stage renal disease registry, 1985-2015 Kidney Res Clin Pract 2015 34 132 139 26484037
7 Alalawi F Bashier A Management of diabetes mellitus in dialysis patients: Obstacles and challenges Diabetes Metab Syndr 2021 15 1025 1036 34000713
8 Eldehni MT Crowley LE Selby NM Challenges in Management of Diabetic Patient on Dialysis Kidney Dial 2022 2 553 564
9 Couchoud C Bolignano D Nistor I Jager KJ Heaf J Heimburger O Van Biesen W European Renal Best Practice (ERBP) Diabetes Guideline Development Group Dialysis modality choice in diabetic patients with end-stage kidney disease: a systematic review of the available evidence Nephrol Dial Transplant 2015 30 310 320 25248364
10 Liu H He Z Hu X Li S Wang L Zhao D Lin Q Liu X Lu F Zhang D Propensity-matched comparison of mortality between peritoneal dialysis and hemodialysis in patients with type 2 diabetes Int Urol Nephrol 2022 54 1373 1381 34657242
11 Xu F Yang Y Wu M Zhou W Wang D Cui W Patients with end-stage renal disease and diabetes had similar survival rates whether they received hemodialysis or peritoneal dialysis Ther Apher Dial 2023 27 59 65 35614543
12 Couchoud C Moranne O Frimat L Labeeuw M Allot V Stengel B Associations between comorbidities, treatment choice and outcome in the elderly with end-stage renal disease Nephrol Dial Transplant 2007 22 3246 3254 17616533
13 Waldum-Grevbo B Leivestad T Reisæter AV Os I Impact of initial dialysis modality on mortality: a propensity-matched study BMC Nephrol 2015 16 179 26519164
14 Elsayed ME Morris AD Li X Browne LD Stack AG Propensity score matched mortality comparisons of peritoneal and in-centre haemodialysis: systematic review and meta-analysis Nephrol Dial Transplant 2020 35 2172 2182 31981353
15 Lee MJ Kwon YE Park KS Kee YK Yoon CY Han IM Han SG Oh HJ Park JT Han SH Yoo TH Kim YL Kim YS Yang CW Kim NH Kang SW Glycemic Control Modifies Difference in Mortality Risk Between Hemodialysis and Peritoneal Dialysis in Incident Dialysis Patients With Diabetes: Results From a Nationwide Prospective Cohort in Korea Medicine (Baltimore) 2016 95 e3118 26986162
16 Weinhandl ED Foley RN Gilbertson DT Arneson TJ Snyder JJ Collins AJ Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients J Am Soc Nephrol 2010 21 499 506 20133483
17 Jin H Ni Z Che X Gu L Zhu M Yuan J Huang J Gu A Jin Y Yan H Wang Q Yu Z Zhou W Fang W Peritoneal Dialysis as an Option for Unplanned Dialysis Initiation in Patients with End-Stage Renal Disease and Diabetes Mellitus Blood Purif 2019 47 52 57 30223256
18 Yeates K Zhu N Vonesh E Trpeski L Blake P Fenton S Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada Nephrol Dial Transplant 2012 27 3568 3575 22391139
19 Wang IK Liang WM Lin CL Liu YL Chang CT Yen TH Huang CC Sung FC Impact of dialysis modality on the survival of patients with end-stage renal disease and prior stroke Int Urol Nephrol 2016 48 139 147 26560476
20 Wang IK Lin CL Yen TH Lin SY Sung FC Comparison of survival between hemodialysis and peritoneal dialysis patients with end-stage renal disease in the era of icodextrin treatment Eur J Intern Med 2018 50 69 74 29208453
21 Kim HJ Park JT Han SH Yoo TH Park HC Kang SW Kim KH Ryu DR Kim H The pattern of choosing dialysis modality and related mortality outcomes in Korea: a national population-based study Korean J Intern Med 2017 32 699 710 28651309
22 Kearney J Gnudi L The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes Pharmaceutics 2023 15
23 Shubrook JH Neumiller JJ Wright E Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations Postgrad Med 2022 134 376 387 34817311
24 Xue C Gu YY Cui CJ Zhou CC Wang XD Ruan MN Huang LX Chen SX Yang B Chen XJ Qian YX Wu J Zhao XZ Zhang YQ Mei CL Zhang SL Xu J Mao ZG New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review Nephrol Dial Transplant 2020 35 1412 1419 31236586
25 Takatori Y Akagi S Sugiyama H Inoue J Kojo S Morinaga H Nakao K Wada J Makino H Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial Clin J Am Soc Nephrol 2011 6 1337 1344 21493740
26 Jin YP Su XF Yin GP Xu XH Lou JZ Chen JJ Zhou Y Lan J Jiang B Li Z Lee KO Ye L Ma JH Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy J Diabetes Complications 2015 29 395 399 25681043
27 Li J Zhang R Wu Z Guo J Wang Z Li S Li C Yang G Cheng X Blood Glucose Fluctuation in Older Adults with Diabetes Mellitus and End-Stage Renal Disease on Maintenance Hemodialysis: An Observational Study Diabetes Ther 2022 13 1353 1365 35689733
28 Jung HS Kim HI Kim MJ Yoon JW Ahn HY Cho YM Oh KH Joo KW Lee JG Kim SY Park KS Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system Diabetes Technol Ther 2010 12 801 807 20809681
29 Hayashi A Shimizu N Suzuki A Matoba K Momozono A Masaki T Ogawa A Moriguchi I Takano K Kobayashi N Shichiri M Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia Diabetes Care 2021 44 1647 1656 34045240
30 Burmeister JE Scapini A da Rosa Miltersteiner D da Costa MG Campos BM Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis Nephrol Dial Transplant 2007 22 1184 1189 17272314
31 Chen XX Duan Y Zhou Y Effects of Hemodialysis and Peritoneal Dialysis on Glycometabolism in Patients with End-Stage Diabetic Nephropathy Blood Purif 2021 50 506 512 33302273
32 Guo Q Chen Y Yang L Zhu X Zhang X Zhao Q Zhuang X Wu Y Luo P Cui W Influence of Early-Onset Peritonitis on Mortality and Clinical Outcomes in ESRD Patients with Diabetes Mellitus on Peritoneal Dialysis: A Retrospective Multicenter Study Blood Purif 2022 51 280 287 34638121
33 Meng LF Yang LM Zhu XY Zhang XX Li XY Zhao J Liu SC Zhuang XH Luo P Cui WP Comparison of clinical features and outcomes in peritoneal dialysis-associated peritonitis patients with and without diabetes: A multicenter retrospective cohort study World J Diabetes 2020 11 435 446 33133391
34 Nessim SJ Bargman JM Austin PC Nisenbaum R Jassal SV Predictors of peritonitis in patients on peritoneal dialysis: results of a large, prospective Canadian database Clin J Am Soc Nephrol 2009 4 1195 1200 19406969
35 He F Wu X Xia X Peng F Huang F Yu X Pneumonia and mortality risk in continuous ambulatory peritoneal dialysis patients with diabetic nephropathy PLoS One 2013 8 e61497 23585903
36 Ueda R Nakao M Maruyama Y Nakashima A Yamamoto I Matsuo N Tanno Y Ohkido I Ikeda M Yamamoto H Yokoyama K Yokoo T Effect of diabetes on incidence of peritoneal dialysis-associated peritonitis PLoS One 2019 14 e0225316 31830041
37 Chang HH Chang CH Hsiao CY Kao SY Chen JY Chen TH Tsai PJ Diabetes Is the Most Critical Risk Factor of Adverse Complications After Peritoneal Dialysis Catheter Placement Front Med (Lausanne) 2021 8 719345 34778285
38 Lin J Ye H Li J Qiu Y Wu H Yi C Lu S Chen J Mao H Huang F Yu X Yang X Prevalence and risk factors of exit-site infection in incident peritoneal dialysis patients Perit Dial Int 2020 40 164 170 32072873
39 Lee SM Min YS Son YK Kim SE An WS Comparison of clinical outcome between incremental peritoneal dialysis and conventional peritoneal dialysis: a propensity score matching study Ren Fail 2021 43 1222 1228 34396922
40 Liu R Ye H Peng Y Yi C Lin J Wu H Diao X Mao H Huang F Yang X Incremental peritoneal dialysis and survival outcomes: a propensity-matched cohort study J Nephrol 2023 36 1907 1919 37603146
41 Sandrini M Vizzardi V Valerio F Ravera S Manili L Zubani R Lucca BJ Cancarini G Incremental peritoneal dialysis: a 10 year single-centre experience J Nephrol 2016 29 871 879 27582136
42 Yap HY Pang SC Tan CS Tan YL Goh N Achudan S Lee KG Tan RY Choong LH Chong TT Catheter-related complications and survival among incident hemodialysis patients in Singapore J Vasc Access 2018 19 602 608 29582680
43 Hasanoglu I Guner R Sahin S Yılmaz Karadag F Parmaksiz E Atalay HV Alısır Ecder S Arslan Gulen T Atan Ucar Z Karabay O Sipahi S Kaya Kılıc E Duranay M Yapar D Dogan İ Ersoz G Turkmen G Kıykım AA Surveillance of hemodialysis related infections: a prospective multicenter study Sci Rep 2022 12 22240 36564392
44 Shima H Okamoto T Tashiro M Inoue T Masaki C Tanaka Y Tada H Takamatsu N Wariishi S Kawahara K Okada K Nishiuchi T Minakuchi J Clinical Characteristics and Risk Factors for Mortality due to Bloodstream Infection of Unknown Origin in Hemodialysis Patients: A Single-Center, Retrospective Study Blood Purif 2021 50 238 245 32892202
45 Johansen KL Chertow GM Gilbertson DT Ishani A Israni A Ku E Li S Li S Liu J Obrador GT Schulman I Chan K Abbott KC O'Hare AM Powe NR Roetker NS Scherer JS St Peter W Snyder J Winkelmayer WC Wong SPY Wetmore JB US Renal Data System 2022 Annual Data Report: Epidemiology of Kidney Disease in the United States Am J Kidney Dis 2023 81 A8 A11 36822739
46 Chaudry MS Gislason GH Kamper AL Rix M Larsen AR Petersen A Andersen PS Skov RL Fosbøl EL Westh H Schønheyder HC Benfield TL Fowler VG Jr Torp-Pedersen C Bruun NE Increased risk of Staphylococcus aureus bacteremia in hemodialysis-A nationwide study Hemodial Int 2019 23 230 238 30779302
47 Lee CC Sun CY Wu MS Long-term modality-related mortality analysis in incident dialysis patients Perit Dial Int 2009 29 182 190 19293356
48 Aslam N Bernardini J Fried L Burr R Piraino B Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients Clin J Am Soc Nephrol 2006 1 1226 1233 17699352
49 Iglesias P Bajo MA Selgas R Díez JJ Thyroid dysfunction and kidney disease: An update Rev Endocr Metab Disord 2017 18 131 144 27864708
50 McCullough PA Chan CT Weinhandl ED Burkart JM Bakris GL Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease Am J Kidney Dis 2016 68 S5 S14 27772643
51 Grzywacz A Lubas A Niemczyk S Inferior Nutritional Status Significantly Differentiates Dialysis Patients with Type 1 and Type 2 Diabetes Nutrients 2023 15
52 Lee SW Lee NR Son SK Kim J Sul AR Kim Y Park JT Lee JP Ryu DR Comparative study of peritoneal dialysis versus hemodialysis on the clinical outcomes in Korea: a population-based approach Sci Rep 2019 9 5905 30976069
53 Khoo CY Gao F Choong HL Tan WXA Koniman R Fam JM Yeo KK Death and cardiovascular outcomes in end-stage renal failure patients on different modalities of dialysis Ann Acad Med Singap 2022 51 136 142 35373236
54 Wang IK Lu CY Lin CL Liang CC Yen TH Liu YL Sung FC Comparison of the risk of de novo cardiovascular disease between hemodialysis and peritoneal dialysis in patients with end-stage renal disease Int J Cardiol 2016 218 219 224 27236118
55 Zou M Xie J Lan L Zhang Y Tian L Chen M Yan Y Safety and efficacy of hemodialysis and peritoneal dialysis in treating end-stage diabetic nephropathy: a meta-analysis of randomized controlled trials Int Urol Nephrol 2022 54 2901 2909 35426589
56 Hu PJ Chen YW Chen TT Sung LC Wu MY Wu MS Impact of dialysis modality on major adverse cardiovascular events and all-cause mortality: a national population-based study Nephrol Dial Transplant 2021 36 901 908 33313719
57 Zhang S Li H Cai X Zhao C Cao J The association between serum cystatin C and residual renal function in peritoneal dialysis patients Ther Apher Dial 2022 26 1241 1246 35253373
58 Brener ZZ Thijssen S Kotanko P Kuhlmann MK Bergman M Winchester JF Levin NW The impact of residual renal function on hospitalization and mortality in incident hemodialysis patients Blood Purif 2011 31 243 251 21242677
59 Kendrick J Teitelbaum I Strategies for improving long-term survival in peritoneal dialysis patients Clin J Am Soc Nephrol 2010 5 1123 1131 20430945
60 Horinek A Misra M Does residual renal function decline more rapidly in hemodialysis than in peritoneal dialysis? Adv Perit Dial 2004 20 137 140 15384814
61 Shen Q Fang X Zhai Y Rao J Chen J Miao Q Gong Y Yu M Zhou Q Xu H Risk factors for loss of residual renal function in children with end-stage renal disease undergoing automatic peritoneal dialysis Perit Dial Int 2020 40 368 376 32063214
62 Htay H Cho Y Pascoe EM Darssan D Hawley C Johnson DW balANZ trial investigators Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial Perit Dial Int 2017 37 283 289 27935537
63 Justo P Sanz AB Egido J Ortiz A 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells Diabetes 2005 54 2424 2429 16046310
64 Tanriover C Ucku D Basile C Tuttle KR Kanbay M On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease J Nephrol 2022 35 2191 2204 35819749
65 Lee Y Chung SW Park S Ryu H Lee H Kim DK Joo KW Ahn C Lee J Oh KH Incremental Peritoneal Dialysis May be Beneficial for Preserving Residual Renal Function Compared to Full-dose Peritoneal Dialysis Sci Rep 2019 9 10105 31300708
66 Liu X Dai C Advances in Understanding and Management of Residual Renal Function in Patients with Chronic Kidney Disease Kidney Dis (Basel) 2017 2 187 196 28232935
67 Tam P Peritoneal Dialysis and Preservation of Residual Renal Function Perit Dial Int 2009 29 108 110 19164260
68 Floria I Kontele I Grammatikopoulou MG Sergentanis TN Vassilakou T Quality of Life of Hemodialysis Patients in Greece: Associations with Socio-Economic, Anthropometric and Nutritional Factors Int J Environ Res Public Health 2022 19
69 Brown EA Zhao J McCullough K Fuller DS Figueiredo AE Bieber B Finkelstein FO Shen J Kanjanabuch T Kawanishi H Pisoni RL Perl J PDOPPS Patient Support Working Group Burden of Kidney Disease, Health-Related Quality of Life, and Employment Among Patients Receiving Peritoneal Dialysis and In-Center Hemodialysis: Findings From the DOPPS Program Am J Kidney Dis 2021 78 489 500.e1 33872688
70 Sun H Zhuang Y Gao L Xu N Xiong Y Yuan M Lu J Ye J Impact of dialysis modality conversion on the health-related quality of life of peritoneal dialysis patients: a retrospective cohort study in China PeerJ 2022 10 e12793 35111408
71 Cepeda Marte JL Javier A Ruiz-Matuk C Paulino-Ramirez R Quality of Life and Nutritional Status in diabetic patients on hemodialysis Diabetes Metab Syndr 2019 13 576 580 30641769
72 Dembowska E Jaroń A Gabrysz-Trybek E Bladowska J Gacek S Trybek G Quality of Life in Patients with End-Stage Renal Disease Undergoing Hemodialysis J Clin Med 2022 11
73 Alencar SBV de Lima FM Dias LDA Dias VDA Lessa AC Bezerra JM Apolinário JF de Petribu KC Depression and quality of life in older adults on hemodialysis Braz J Psychiatry 2020 42 195 200 31389496
74 Mathew N Davies M Kaldine F Cassimjee Z Comparison of quality of life in patients with advanced chronic kidney disease undergoing haemodialysis, peritoneal dialysis and conservative management in Johannesburg, South Africa: a cross-sectional, descriptive study BMC Psychol 2023 11 151 37158906
75 Muehrer RJ Schatell D Witten B Gangnon R Becker BN Hofmann RM Factors affecting employment at initiation of dialysis Clin J Am Soc Nephrol 2011 6 489 496 21393489
76 Iyasere O Brown EA Johansson L Davenport A Farrington K Maxwell AP Collinson H Fan S Habib AM Stoves J Woodrow G Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis Clin Kidney J 2019 12 262 268 30976407
77 Raoofi S Pashazadeh Kan F Rafiei S Hoseinipalangi Z Rezaei S Ahmadi S Masoumi M Noorani Mejareh Z Roohravan Benis M Sharifi A Shabaninejad H Kiaee ZM Ghashghaee A Hemodialysis and peritoneal dialysis-health-related quality of life: systematic review plus meta-analysis BMJ Support Palliat Care 2023 13 365 373
78 Rayner HC Zepel L Fuller DS Morgenstern H Karaboyas A Culleton BF Mapes DL Lopes AA Gillespie BW Hasegawa T Saran R Tentori F Hecking M Pisoni RL Robinson BM Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis 2014 64 86 94 24529994
79 Ong S Barker-Finkel J Allon M Long-term outcomes of arteriovenous thigh grafts in hemodialysis patients: a comparison with tunneled dialysis catheters Clin J Am Soc Nephrol 2013 8 804 809 23371958
80 Surendra NK Abdul Manaf MR Hooi LS Bavanandan S Mohamad Nor FS Shah Firdaus Khan S Ong LM Abdul Gafor AH Health related quality of life of dialysis patients in Malaysia: Haemodialysis versus continuous ambulatory peritoneal dialysis BMC Nephrol 2019 20 151 31039745
81 Cameron JI Whiteside C Katz J Devins GM Differences in quality of life across renal replacement therapies: a meta-analytic comparison Am J Kidney Dis 2000 35 629 637 10739783
82 Wu AW Fink NE Marsh-Manzi JV Meyer KB Finkelstein FO Chapman MM Powe NR Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures J Am Soc Nephrol 2004 15 743 753 14978177
83 Zeng B Wang Q Wu S Lin S Li Y Jiang W Guo R Zhou F Lin K Cognitive Dysfunction and Health-Related Quality of Life in Patients with End-Stage Renal Disease Undergoing Hemodialysis in Comparison with Patients Undergoing Peritoneal Dialysis: A Cross-Sectional Study Med Sci Monit 2022 28 e934282 35124688
84 Bargman JM Girsberger M Visions in a Crystal Ball: The Future of Peritoneal Dialysis Blood Purif 2018 45 218 223 29478058
85 Iyasere OU Brown EA Johansson L Huson L Smee J Maxwell AP Farrington K Davenport A Quality of Life and Physical Function in Older Patients on Dialysis: A Comparison of Assisted Peritoneal Dialysis with Hemodialysis Clin J Am Soc Nephrol 2016 11 423 430 26712808
86 Roggeri A Roggeri DP Zocchetti C Bersani M Conte F ReNe (Renal Lombardy Network) Additional contributors from ReNe Network Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis J Nephrol 2017 30 263 269 27165160
87 Berger A Edelsberg J Inglese GW Bhattacharyya SK Oster G Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease Am J Manag Care 2009 15 509 518 19670954
88 Chang YT Hwang JS Hung SY Tsai MS Wu JL Sung JM Wang JD Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score Sci Rep 2016 6 30266 27461186
89 Shukri A Mettang T Scheckel B Schellartz I Simic D Scholten N Müller M Stock S Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View-A Propensity Score Matched Analysis Int J Environ Res Public Health 2022 19
90 Wong CKH Chen J Fung SKS Mok M Cheng YL Kong I Lo WK Lui SL Chan TM Lam CLK Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy BMC Nephrol 2020 21 42 32019528
91 Kwong VW Li PK Peritoneal Dialysis in Asia Kidney Dis (Basel) 2015 1 147 156 27536675
92 Schmicker R Nutritional treatment of hemodialysis and peritoneal dialysis patients Artif Organs 1995 19 837 841 8573005
93 Kang GH Kim YN Shin HS Relationship between geriatric nutritional risk index and subpopulation lymphocyte counts in patients undergoing hemodialysis and peritoneal dialysis Ren Fail 2016 38 1589 1593 27934551
94 Leinig CE Moraes T Ribeiro S Riella MC Olandoski M Martins C Pecoits-Filho R Predictive value of malnutrition markers for mortality in peritoneal dialysis patients J Ren Nutr 2011 21 176 183 21193323
95 Lowrie EG Lew NL Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 1990 15 458 482 2333868
96 Wu X Meng J Zhou L Zhan X Wen Y Wang X Feng X Wang N Peng F Wu J Albumin to Total Cholesterol Ratio and Mortality in Peritoneal Dialysis Front Med (Lausanne) 2022 9 896443 35755025
97 Prasad N Gupta A Sinha A Sharma RK Kumar A Kumar R Changes in nutritional status on follow-up of an incident cohort of continuous ambulatory peritoneal dialysis patients J Ren Nutr 2008 18 195 201 18267212
98 Prasad N Gupta A Sinha A Singh A Sharma RK Kaul A Impact of stratification of comorbidities on nutrition indices and survival in patients on continuous ambulatory peritoneal dialysis Perit Dial Int 2009 29 Suppl 2 S153 S157 19270207
99 Silva LF Lopes GB Matos CM Brito KQ Amoedo MK Azevedo MF Sá Araújo MJ Martins MS Lopes AA Gastrointestinal symptoms and nutritional status in women and men on maintenance hemodialysis J Ren Nutr 2012 22 327 335 22071220
100 Boaz M Azoulay O Kaufman-Shriqui V Weinstein T Status of Nutrition In Hemodialysis Patients Survey (SNIPS): Malnutrition risk by diabetes status Diabet Med 2021 38 e14543 33583032
101 Bataille S Landrier JF Astier J Cado S Sallette J Giaime P Sampol J Sichez H Ollier J Gugliotta J Serveaux M Cohen J Darmon P Haemodialysis patients with diabetes eat less than those without: A plea for a permissive diet Nephrology (Carlton) 2017 22 712 719 27287085
102 Sá Martins V Aguiar L Dias C Lourenço P Pinheiro T Velez B Borges N Adragão T Calhau C Macário F Predictors of nutritional and inflammation risk in hemodialysis patients Clin Nutr 2020 39 1878 1884 31427179
103 Kang SH Do JY Kim JC Association Between Alkaline Phosphatase and Muscle Mass, Strength, or Physical Performance in Patients on Maintenance Hemodialysis Front Med (Lausanne) 2021 8 657957 34079810
104 Salamon K Woods J Paul E Huggins C Peritoneal dialysis patients have higher prevalence of gastrointestinal symptoms than hemodialysis patients J Ren Nutr 2013 23 114 118 22633989
105 Xu XD Han X Yang Y Li X Comparative study on the efficacy of peritoneal dialysis and hemodialysis in patients with end-stage diabetic nephropathy Pak J Med Sci 2020 36 1484 1489 33235561
106 Cianciaruso B Brunori G Kopple JD Traverso G Panarello G Enia G Strippoli P De Vecchi A Querques M Viglino G Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients Am J Kidney Dis 1995 26 475 486 7645556
107 Lo WK Bargman JM Burkart J Krediet RT Pollock C Kawanishi H Blake PG ISPD Adequacy of Peritoneal Dialysis Working Group Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis Perit Dial Int 2006 26 520 522 16973505
108 Guo Q Yi C Li J Wu X Yang X Yu X Prevalence and risk factors of fluid overload in Southern Chinese continuous ambulatory peritoneal dialysis patients PLoS One 2013 8 e53294 23341936
109 Zoccali C Moissl U Chazot C Mallamaci F Tripepi G Arkossy O Wabel P Stuard S Chronic Fluid Overload and Mortality in ESRD J Am Soc Nephrol 2017 28 2491 2497 28473637
110 Jin Y Huang X Zhang C Xie J Ren H Impact of fluid overload on blood pressure variability in patients on peritoneal dialysis Ren Fail 2022 44 2066 2072 36415108
